Status:
COMPLETED
St. John's Wort for the Treatment of Generalized Social Anxiety Disorder (GSAD)
Lead Sponsor:
National Center for Complementary and Integrative Health (NCCIH)
Conditions:
Anxiety Disorders
Mental Health
Eligibility:
All Genders
18+ years
Phase:
PHASE2
PHASE3
Brief Summary
This study will determine whether the herbal product St. John's wort is safe and effective in treating generalized social anxiety disorder (GSAD). Study hypothesis: Hypericum perforatum (St. John's w...
Detailed Description
The use of complementary and alternative medicine (CAM) has grown dramatically over the last decade. Botanical treatments originating from plants have become especially popular for treating conditions...
Eligibility Criteria
Inclusion
- Diagnosis of GSAD
- Brief Social Phobia Scale (BSPS) score of 20 or higher
Exclusion
- Comorbid anxiety, depressive, or bipolar disorders
- Schizophrenia
- Cognitive impairment
- Substance abuse or dependence within 1 year prior to study entry
- Any unstable medical condition
- Clinically significant laboratory or electrocardiogram (EKG) abnormality
- Currently use psychotropic medications or may need psychotropic medication during the study
- Psychotherapy within 6 weeks prior to study entry
- Failed a previous trial of St. John's wort at doses of 1800 mg/day or greater
- Pregnancy or breastfeeding
Key Trial Info
Start Date :
August 1 2002
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2006
Estimated Enrollment :
56 Patients enrolled
Trial Details
Trial ID
NCT00118833
Start Date
August 1 2002
End Date
June 1 2006
Last Update
September 26 2007
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Duke University Medical Center
Durham, North Carolina, United States, 27710